From the Research
It is generally recommended to wait at least 7-14 days after port catheter implantation before starting aflibercept (VEGF inhibitor) therapy. This waiting period allows for proper wound healing at the implantation site and reduces the risk of complications. VEGF inhibitors like aflibercept can impair wound healing by blocking angiogenesis, which is essential for tissue repair. Starting the medication too soon after port placement could potentially lead to delayed healing, increased risk of infection, or port-related complications.
The exact timing may vary based on individual patient factors such as age, overall health status, healing capacity, and the urgency of starting the anti-VEGF therapy. If the port site shows good healing with no signs of infection or complications before the 14-day mark, treatment might be initiated earlier in consultation with the healthcare provider. Conversely, if there are any concerns about wound healing or signs of infection, the waiting period might need to be extended beyond two weeks.
Some studies have shown that starting chemotherapy immediately after port catheter implantation can be safe in certain settings 1, but these findings may not directly apply to the use of VEGF inhibitors like aflibercept, which have specific implications for wound healing. The efficacy and safety of aflibercept in combination with chemotherapy have been demonstrated in various studies 2, 3, 4, but the optimal timing for initiating aflibercept after port catheter implantation is not explicitly addressed in these studies.
However, considering the potential risks associated with impaired wound healing, it is prudent to prioritize caution and adhere to a waiting period that allows for adequate healing before starting aflibercept therapy. The management of central venous access ports and catheters in outpatient chemotherapy, including the assessment of complications, is crucial for patient care 5.
In clinical practice, the decision to start aflibercept after port catheter implantation should be individualized, taking into account the patient's overall condition, the specific details of their port placement, and the clinical context in which the VEGF inhibitor is being used. The primary goal is to balance the need for timely initiation of anti-VEGF therapy with the risk of complications related to wound healing and port catheter management.